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Abstract
Background: Neurotropic flaviviruses such as tick-borne encephalitis virus (TBEV), Japanese encephalitis virus (JEV),
West Nile virus (WNV), and Zika virus (ZIKV) are causative agents of severe brain-related diseases including
meningitis, encephalitis, and microcephaly. We have previously shown that local type I interferon response within
the central nervous system (CNS) is involved in the protection of mice against tick-borne flavivirus infection.
However, the cells responsible for mounting this protective response are not defined.
Methods: Primary astrocytes were isolated from wild-type (WT) and interferon alpha receptor knock out (IFNAR−/−)
mice and infected with neurotropic flaviviruses. Viral replication and spread, IFN induction and response, and
cellular viability were analyzed. Transcriptional levels in primary astrocytes treated with interferon or supernatant
from virus-infected cells were analyzed by RNA sequencing and evaluated by different bioinformatics tools.
Results: Here, we show that astrocytes control viral replication of different TBEV strains, JEV, WNV, and ZIKV. In
contrast to fibroblast, astrocytes mount a rapid interferon response and restrict viral spread. Furthermore, basal
expression levels of key interferon-stimulated genes are high in astrocytes compared to mouse embryonic
fibroblasts. Bioinformatic analysis of RNA-sequencing data reveals that astrocytes have established a basal antiviral
state which contributes to the rapid viral recognition and upregulation of interferons. The most highly upregulated
pathways in neighboring cells were linked to type I interferon response and innate immunity. The restriction in viral
growth was dependent on interferon signaling, since loss of the interferon receptor, or its blockade in wild-type cells,
resulted in high viral replication and virus-induced cytopathic effects. Astrocyte supernatant from TBEV-infected cells
can restrict TBEV growth in astrocytes already 6 h post infection, the effect on neurons is highly reinforced, and
astrocyte supernatant from 3 h post infection is already protective.
Conclusions: These findings suggest that the combination of an intrinsic constitutive antiviral response and the fast
induction of type I IFN production by astrocytes play an important role in self-protection of astrocytes and suppression
of flavivirus replication in the CNS.
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Background
The genus Flavivirus belonging to the family Flaviviridae
include important pathogens causing severe human
disease including meningitis, encephalitis, hemorrhagic
fevers, and microcephaly. The most significant neu-
rotropic flaviviruses are arthropod-borne tick-borne
encephalitis virus (TBEV), West Nile virus (WNV),
Japanese encephalitis virus (JEV), and Zika virus (ZIKV).
TBEV is transmitted by Ixodes ticks, whereas WNV, JEV,
and ZIKV are transmitted via mosquitos. No treatments
are available for any of these viral infections, and patients
are dependent on innate and adaptive parts of the host
immune response to fight infections [1–6].
The innate immune system presents a first line of
defense against viral infections, for which type I inter-
ferons (IFNs) are particularly important. After flavivirus
infection, double-stranded RNA (dsRNA) is produced as
an intermediate during viral replication. This is sensed
as a danger signal in the infected cell by pattern recogni-
tion receptors (PRRs) and a signaling cascade is initiated,
which leads to the upregulation of IFNs [7, 8]. IFNs are
powerful cytokines that mediate antiviral effects via both
autocrine and paracrine signaling mechanisms via the IFN
alpha receptor (IFNAR). Binding to IFNAR activates the
downstream kinases Janus kinase 1 and tyrosine kinase 2,
which phosphorylate signal transducer and activator of
transcription-1 and transcription-2 (STAT1, STAT2). To-
gether with interferon regulatory factor-9 (IRF9), these
form a signaling complex referred to as IFN-stimulated
gene factor-3 (ISGF3). ISGF3 translocates to the nucleus
and activates the transcription of a large number of
interferon-stimulated genes (ISGs) by binding to the
interferon response elements. ISGs can inhibit almost
every step of a viral life cycle [9, 10].
In mice, the type I IFN response is essential for
protection against TBEV, JEV, WNV, and ZIKV
infections [11–15]. The CNS has been considered as an
immune-privileged tissue; however, recent studies have
implicated the importance of intrinsic, innate antiviral
responses within the CNS [16–19]. In Langat virus
(LGTV, Langat virus, low-virulent member of TBEV
serogroup) infection, the local type I IFN response in the
CNS has been shown to be critical for the protection of
mice against lethal encephalitis [11]. However, the CNS
cell type responsible for producing IFN during TBEV
infection has not been defined.
While neurons are the main target of neurotropic flavi-
viruses, other cell types might also become infected and
contribute to the resolution of infection [20]. Previous
studies have shown that the IFN response and ISG expres-
sion in neurons restrict neurotropic flavivirus infection in
neurons [19, 21]; however, not much is known about the
role of the IFN response in astrocytes during neurotropic
flavivirus infection. Recent studies have shown that
astrocytes are important IFN-producing cells in various
neurotropic viral infections [18, 22, 23]. Astrocytes are
one of the most abundant cell types in the brain and
mediate diverse supportive functions including ion
homeostasis [24, 25], uptake of glutamate [26], free radical
scavenging [27], and immune regulation [28]. In TBEV
infection, autopsy studies have revealed astrogliosis in post
mortem human brains [20, 29], which has been observed
for WNV and JEV as well [30, 31]. Indeed, astrocytes have
been found to be a site of these infections [32]. However,
only a few astrocytes were found to be infected in
LGTV-infected mice [33]. They resist infection in an
interferon-beta promoter stimulator 1 (IPS-1)-dependent
manner and show an activated phenotype, indicating their
involvement in LGTV clearance. Both rat and human
astrocytes have been shown to be infected in vitro with
TBEV; however, the number of infected cells never
exceeded 20 %, and the infection did not affect astrocyte
viability [34, 35]. Similar findings have also been observed
for other neurotropic flaviviruses [36–39]. Therefore, we
set out to investigate how the type I IFN system in
primary mouse astrocytes contributes to cell survival and
restriction of neurotropic flavivirus growth.
We found that astrocytes respond very quickly after
viral infection by upregulation of type I IFNs. This
upregulation restricts virus replication and spread in
primary cultures and contributes to cell survival. By
RNA sequencing (RNASeq), we could show that
uninfected astrocytes exist in an active antiviral state,
which enables fast recognition and response to viral
infection by upregulating important antiviral ISGs and
that this antiviral state is dependent on IFNAR expression.
Methods
Mice
C57BL/6 (wild-type (WT)) mice and IFNAR−/− mice on
C57BL/6 background were bred at Umeå Transgene
Facility.
Isolation of astrocytes and neurons
The mice were sacrificed between postnatal day 1 and 4
for astrocyte isolation. Cerebral cortices were isolated,
and cells were seeded in poly-D-lysine (Sigma) coated
T75 tissue culture flasks as previously described [40].
Monolayers of astrocytes were shaken at 200 rpm for
1 h to remove microglia and oligodendrocyte precursors
before seeding for experiments. Primary cortical neurons
were derived from cerebral cortices of embryonic day 17
mice. The cortices were isolated, and cells were seeded
in Dulbecco’s modified Eagle’s medium (DMEM, Sigma
D5648-10L) containing 10 % heat-inactivated foetal
bovine serum (FBS, Gibco) and 0.1 U/mL penicillin and
0.1 μg/mL streptomycin (Gibco) in poly-D-lysine (Sigma)
coated 96-well plates as previously described [41]. After
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3 h, the medium was replaced with Neurobasal medium
(Gibco) containing B27 (Gibco), 0.1 U/mL penicillin,
0.1 μg/mL streptomycin, and 2 mM L-glutamine (Gibco).
The neurons were infected at day 7 post seeding.
Viruses and cells
VeroB4 cells were cultured in medium 199/EBSS
(HyClone) containing 10 % FBS, 0.1 U/mL penicillin,
and 0.1 μg/mL streptomycin (Gibco). Mouse embryonic
fibroblasts (MEFs) were grown supplemented with 10 %
FBS, 50 μM β-mercaptoethanol (AppliChem), and 2 μg/
mL tetracycline DMEM (Sigma). TBEV strains Hypr 71
(isolated in 1953 from blood of a patient in the Czech
Republic), Aina (isolated in 1963 in Irkutsk from the
blood of a patient), and Sofjin (isolated in 1937 from
patient in Russia and showed 99 % sequence identity to
strains Sofjin-Chumakov and SofjinKSY with BLAST)
were a kind gift of G. Dobler (the Bundeswehr Institute
of Microbiology, Munich, Germany). JEV (Nakayama
strain) was a kind gift of S. Vene (Folkhälsoinstitutet,
Stockholm, Sweden). WNV (isolated in 2003 in Israel
WNV_0304h_ISR00, passage number 5) is a kind gift of
S. Vene. Stocks were generated in VeroB4 cells. Vesicu-
lar stomatitis virus (VSV)-eGFP was propagated in
VeroB4 cells. ZIKV MR 766 (isolated in 1947 in Zika
Forest, Uganda) was propagated in VeroB4 cells and
originally provided by Robert Shope (Yale Arbovirus
Research Unit, New Haven, CT, USA) as a reference
strain to Jürgen Pilaski (University of Düsseldorf,
Germany), who kindly transferred the strain to the
Bundeswehr Institute of Microbiology, Munich, Germany.
TBEV strains, JEV, and ZIKV are cell culture-adapted
reference strains with an unknown passage history. Cell
monolayers were infected with virus for 1 h at 37 °C.
The virus inoculum was then removed and replaced
with DMEM supplemented with 2 % FBS, 0.1 U/mL
penicillin, and 0.1 μg/mL streptomycin. Viral titers
were determined by focus forming assay as previously
described [42].
RNA isolation and qPCR
Total RNA was isolated at the indicated time points using
Nucleospin RNA II kit (Macherey-Nagel), and cDNA was
synthesized from 200 to 600 ng RNA as previously de-
scribed [42]. mRNA expression of GAPDH, IFNβ, IFNα2,
viperin and tripartite motif 79α (TRIM79α) were detected
by QuantiTect primer assay (Qiagen) and the KAPA SYBR
FAST qPCR kit (KAPA Biosystems) using a StepOnePlus
fast real-time PCR system (Applied Biosystems). TBEV
RNA was quantified using primers previously described
[43] and the KAPA PROBE FAST qPCR kit (KAPA
Biosystems). Gene expression was normalized to the
endogenous GAPDH expression.
Viral spread assay and immunofluorescence
Cells were grown on 96-well plates (Greiner CELLSTAR®),
fixed in 4 % formaldehyde and permeabilized in PBS
containing 0.5 % Triton X-100 and 20 mM glycine. The
cells were stained with primary antibodies; a mouse mono-
clonal TBEV anti-E antibody (Hypr, 1493 1:1000 [44], Sofjin
and Aina, 1786 1:1000 [44]), flavivirus anti-E antibody (JEV,
WNV, and ZIKV, HB112 1:1000, ATCC D1-4G2-4-15 [45]),
and rabbit polyclonal anti-GFAP antibody (1:1000 Abcam,
ab7260 [46]). Secondary antibodies were as follows
(Thermo Fisher Scientific); donkey anti-rabbit Alexa Fluor
488 (A21206), donkey anti-mouse Alexa Fluor 555
(A31570), and goat anti-mouse Alexa Fluor 647 (A21236)
which were diluted 1:500. Nuclear counterstaining was
performed using DAPI (Life Technologies, D1306) 1 μg/
mL. Viral spread was quantified using a TROPHOS Plate
RUNNER HD® (TROPHOS SA, Marseille, France).
Images of immunofluorescence staining were acquired
under a Zeiss Axiovert 25 microscope using an infinity3
luminera® camera.
IFN bioassay
Supernatants from virus-infected astrocytes were inacti-
vated using β-propiolactone (β-PL) (Acros Organics,
269040050), diluted in water to 0.96 % and used at a final
concentration of 0.05 %, incubated at 4 °C for 16 h followed
by 2 h incubation at 37 °C for hydrolysis, performed in
plates (VWR, 734-2325) to avoid acidification of the
samples [47, 48]. The cells (MEFs, astrocytes, or neurons)
were seeded in 96-well plates (Greiner CELLSTAR®) and
treated with β-PL-inactivated supernatants or serially
diluted IFNαB/D [49] (a kind gift of Peter Stäheli, Virology,
University of Freiburg, Freiburg, Germany). The cells were
infected 24 h post treatment with VSV-eGFP (multiplicity
of infection (MOI) 0.01) (MEFs) or TBEV (astrocytes or
neurons) and fixed with 4 % formaldehyde at 16 h post in-
fection (hpi). The number of infected cells was determined
using a TROPHOS Plate RUNNER HD®, and the IFN levels
were quantified using a standard curve (calculated from 1,
5, 10, 50, 100, and 500 U of IFNαB/D).
Western blot
The cells were lyzed, proteins were separated, and
Western blot was performed as previously described [50].
The primary antibodies directed against TBEV E (1493),
actin (rabbit polyclonal anti-actin, 1:2500, Sigma [50]),
and viperin (mouse monoclonal anti-viperin, 1:500 Abcam
[50]) were used.
RNASeq
Primary WT and IFNAR−/− astrocytes were seeded at
200,000 cells per 12-well. Upon reaching confluence, WT
cells were either stimulated with β-PL-inactivated super-
natant from WT astrocytes (24 hpi), 5000 U IFNαB/D [49],
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or left untreated. Six hours after stimulation, total RNA
was isolated using Nucleospin RNA II kit (Macherey-
Nagel) according to the manufacturers’ instructions. One
thousand to three thousand nanograms of RNA was sent
to GATC Biotech (Konstanz, Germany) for RNAseq
(InViewTM Transcriptome Explore).
Bioinformatics
For analyses of the RNASeq data, all treatments were
normalized to their respective control and gene names
were converted to human HGNC gene names before
bioinformatical analyses were performed. Ingenuity
Pathway Analysis (IPA; Ingenuity Systems, http://
www.ingenuity.com/) was used to analyze activated
pathways and predicted upstream activators as previ-
ously described [51, 52]. In brief, activation of Z values
were used to determine activation of pathway or re-
gulators (−2 ≥ Z, significant inhibition; 2 ≤ Z, significant
activation), p values were calculated using right-tailed
Fisher’s exact representing the significance for the over-
lap between dataset and pathway or regulator. Gene set
enrichment analysis (GSEA; http://www.broadinstitute.
org/gsea) was performed to evaluate functional gene sets
that are associated with each of the treatments
compared to controls. The fold-change regulation of the
genes after treatment was used to perform pre-ranked
GSEA. The BIOCARTA, KEGG, and REACTOME
databases were queried; p values were estimated by 100
permutations and a null-distribution of the enrichment
scores. P values were adjusted using the Benjamini-
Hochberg method. A normalized enrichment score
(NES) was computed by mean normalization [53]. The
Connectivity Map database (http://www.lincscloud.org/;
[54]) was used to analyze upstream regulators based on
regulated genes after IFNαB/D or supernatant treatment.
The top 50 expressed genes and top 50 downregulated
genes were selected from, each treatment, per analysis,
and a connectivity score >90 or <−90 was considered
significant.
Blocking of IFNAR receptor
Cells were incubated with DMEM, 10 % heat-inactivated
FBS, and 2 mM glutamine with MAR1-5A3 antibody
(Affymetrix eBioscience, 16-5945-85 [19]) or IgG1 κ iso-
type control (eBioscience, 14-4714-85) at a concentration
of 10 μg/mL for 2 h at 37 °C. After 2 h, the antibodies
were removed, and cells were infected with TBEV for 1 h.
Following removal of the viral infection inoculum, the
medium containing 10 μg/mL antibody was returned to
the cells.
Resazurin viability test
Three hours before the indicated time point, the cells were
treated with 40 μM resazurin; after 3 h of incubation,
fluorescent signal was quantified using a plate reader
(Paradigm, Beckman Coulter).
Statistical analyses
Data from quantitative reverse transcription PCR (qPCR),
bioassay, focus forming assays, and viral spread assays were
analyzed with unpaired t test using GraphPad Prism soft-
ware. Statistical analyses of RNASeq data were performed
by GATC Biotech using Cufflinks [55, 56].
Results
The type I IFN response limits TBEV replication in
astrocytes
Astrocytes are the most abundant glial cell type in the
brain and an important source of type I IFN during vari-
ous neurotropic viral infections [18, 22, 23]. To investi-
gate the importance of type I IFNs for astrocyte function
in neurotropic flavivirus infection, primary astrocytes
were isolated from wild-type (WT) and IFNAR−/− mice.
These were infected with TBEV strain Hypr at a MOI of
0.1 and analyzed by immunofluorescence (Fig. 1a). Both
WT and IFNAR−/− infected astrocytes expressed the
characteristic marker glial fibrillary acidic protein
(GFAP) and were found positive for TBEV E (Fig. 1a).
Viral replication was analyzed over time, and low viral
titers and replication were observed in WT astrocytes. In
contrast, TBEV titers and RNA replication increased
dramatically in IFNAR−/− astrocytes over time (Fig. 1b, c).
Infection was also analyzed in MEFs where an
unrestricted growth profile was observed in both WT and
IFNAR−/− cells (Fig. 1d, e). Our results indicate that
IFNAR restricts TBEV replication in a cell type-dependent
manner.
IFNAR restricts neurotropic flavivirus spread in astrocytes
The type I IFN response could limit viral replication by
different mechanisms: (i) restricting the spread of
progeny viruses to neighboring cells, (ii) reducing overall
viral replication, or (iii) both. To investigate this, WT
and IFNAR−/− astrocytes and MEFs were infected by
TBEV at a MOI of 0.1, stained by immunofluorescence,
and the numbers of infected cells were quantified (Fig. 2a
shows a representative picture of infected wells). Even
though the initial infections (24 hpi) in WT and IFNAR−/−
astrocytes were comparable, the outcome of infection
differed dramatically. Infection of WT astrocytes was low
and never exceeded 20 %; however, infection of IFNAR−/−
astrocytes was significantly higher at the late time points,
reaching an average of 69 % at 72 hpi (Fig. 2b). In MEFs,
IFNAR expression failed to restrict TBEV spread, and no
difference were observed between WT and IFNAR−/− cells
(data not shown). These results suggest that IFNAR
restricts the spread of TBEV in astrocytes.
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TBEV can be categorized into European, Siberian, and
Far Eastern subtypes according to phylogenetic differ-
ences. The Siberian and Far Eastern subtypes have been
associated with more severe disease compared to the
European subtype [57, 58]. Increased pathogenicity could
be due to several factors, e.g., ability to interfere with the
type I IFN response. Therefore, viral growth of two
reference strains; the Siberian Aina and Far Eastern Sofjin,
was analyzed in WT and IFNAR−/− astrocytes (Fig. 2c, d).
Similar to the European subtype of TBEV, an interferon
response also restricted the spread of Siberian and Far
Eastern TBEV subtypes (Fig. 2c, d). Although the type I
IFN response plays an important role in mosquito-borne
neurotropic flavivirus (WNV, JEV, and ZIKV) infections in
vivo [12–14, 59, 60], the specific role of IFNAR signaling
in restricting viral growth in astrocytes is unknown. WT
and IFNAR−/− astrocytes were infected with JEV, WNV,
and ZIKV, and the numbers of infected cells were deter-
mined (Fig. 2e–g). For all three mosquito-borne viruses,
the IFN response was required for the restriction of viral
spread in astrocytes. Our data shows that the type I IFN
response in astrocytes efficiently restricts the spread of
both tick- and mosquito-borne neurotropic flaviviruses.
Astrocytes induce a rapid IFN response upon TBEV
infection
Previous studies have indicated the importance of
astrocyte-produced IFN in various viral infections
[18, 22, 23]. The observed differences in the impact of
IFNAR on astrocytes and MEFs could either be explained
by the ability to respond to, or the capacity to induce, IFN
following infection. To determine the impact of the type I
IFN response in the overall antiviral response, astrocytes
and MEFs were pretreated with IFNαB/D [49] Sixteen
hours before TBEV infection (Fig. 3a, b). TBEV growth was
inhibited to a similar extent showing that both cell-types
were able to mount a strong antiviral response upon IFN
treatment. Thus, the ability to respond to IFN (Fig. 3a, b)
could not explain the lack of control of viral replication in
IFNAR−/− MEFs (Fig. 1d, e). To test whether astrocytes and
MEFs differ in their capability to induce type I IFNs after
infection, IFNβ and IFNα2 mRNAs were quantified by real-
time qPCR (Fig. 3c, d). Interestingly, the IFN responses in
the two cell types were quite different. Whereas astrocytes
induced IFN mRNA after 6 h, the response in MEFs was
delayed and IFNβ and IFNα2 mRNAs were detected only
after 24 or 48 hpi, respectively. Next, a VSV-GFP-based
Fig. 1 IFNAR restricts TBEV replication in astrocytes. Primary astrocytes were isolated from WT and IFNAR−/− mice and infected with Hypr MOI 0.1.
a Cell were stained 72 hpi with GFAP (astrocytes), TBEV E protein, and DAPI. Scale bar 193 μm. Primary astrocytes (b, c) and MEF (d, e) were
infected with TBEV (MOI 0.1), and viral growth was determined over time by focus forming assay (b, d) and qPCR (c, e). Data are cumulative from
at least two independent experiments performed in triplicates (n = 6). Asterisks indicate data were statistically significant: ***p < 0.0001
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bioassay on MEFs was applied to quantify secreted IFN,
and astrocytes were found to secrete higher levels of IFNs
24 hpi compared to MEFs (Fig. 3e). These data indicate that
astrocytes react to viral infection by the induction of IFNs
much more rapidly than MEFs.
In order to define the time point after infection at
which astrocytes initiate an antiviral response and limit
viral spread in astrocytes, a TBEV-based bioassay on
astrocytes was developed. Pretreated astrocytes were
infected, and the numbers of infected cells were
quantified at 48 hpi (Fig. 3f ). The supernatants showed
an inhibitory effect as early as 6 hpi on WT, but not on
IFNAR−/− cells, suggesting a very early type I IFN-
mediated antiviral effect.
The antiviral effect of the supernatant was further
investigated using qPCR as a more sensitive method of
quantifying viral replication. Sixteen hours before TBEV
infection, the cells were treated with either supernatant
of 24-h TBEV-infected cells or IFNαB/D. The cells were
infected with TBEV, and total RNA was extracted 48 hpi
to detect TBEV RNA (Fig. 3g). Pretreatment with
supernatant of infected cells and 5000 U IFNαB/D had a
similar inhibitory effect on TBEV replication in WT
astrocytes. However, no difference in viral replication
was detected in IFNAR−/− astrocytes treated with or
without supernatant, indicating a type I IFN-dependent
antiviral effect. These results further suggest that the
rapid type I IFN response is responsible for limiting viral
infection and replication in astrocytes.
IFNAR mediates antiviral preparedness in astrocytes
Our data indicate that WT astrocytes are quite resistant
to viral infection and that the main effectors in the
supernatant from virus-infected astrocytes are type I
Fig. 2 IFNAR restricts neurotropic flavivirus spread in astrocytes. Primary astrocytes isolated from WT and IFNAR−/− mice were infected with 0.1
MOI of different flaviviruses. A number of infected cells were determined by immunofluorescence assay staining for DAPI (blue) and flavivirus E
protein (red). Scale bar 0.66 mm. a Representative picture of TBEV-infected WT and IFNAR−/− astrocytes and MEFs (resolution 1024 × 1024) 72 hpi.
a, b Hypr European subtype. c Aina, Siberian subtype. d Sofjin Far Eastern subtype. e JEV. f WNV. g ZIKV. Data are cumulative from at least two
independent experiments n = 8.*p < 0.05, ***p < 0.001, ****p < 0.0001
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IFNs. To characterize these responses in more detail, we
analyzed transcriptional regulation by RNAseq. Gene ex-
pression levels from uninfected IFNAR−/− astrocytes and
IFNαB/D-treated, or supernatant-treated, WT astrocytes
were compared to untreated WT astrocytes. Fold-change
values of at least twofold over the uninfected control
and a q value of <0.05 were considered indicative of up-
or downregulation. Our data yielded 732 upregulated
transcripts while 944 were found to be downregulated in
IFNAR−/− astrocytes. Treatment of primary astrocytes
with IFNαB/D or supernatant led to 634 or 1092 upreg-
ulated and 149 or 423 downregulated genes, respectively
(Additional file 1: Table S1).
The majority of all significantly regulated genes
showed a unique pattern of regulation for each sample
(Fig. 4a–c). Looking more closely at the differences be-
tween astrocytes treated with supernatant or IFNαB/D,
relatively few genes were downregulated, and we
detected 257 genes upregulated in both samples, out of
total 894 upregulated genes in the supernatant and 550
in IFNαB/D (Fig. 4b, c). This indicated that although the
main transcriptional response is type I IFN-dependent
and overlaps with IFNαB/D treatment, virus infection
induces numerous other IFN-independent responses in
neighboring, uninfected astrocytes.
Only 112 transcripts were found to be significantly
regulated between all three samples compared to WT
(Fig. 4a). However, they showed a very different expres-
sion profile (Fig. 4d). Interestingly, IFNAR-deficient
astrocytes showed lower levels of PRR, innate immune
signaling, transcription factors, ISGs, and adaptive
immune response compared to untreated WT astrocytes,
whereas, IFNαB/D- and supernatant-treated WT astro-
cytes showed an upregulated profile (Fig. 4d, Additional
file 1: Table S2).
WT astrocytes show higher expression and rapid
induction of antiviral ISGs after TBEV infection
The susceptibility of IFNAR−/− astrocytes to flavivirus
infection might be due to lowered basal expression of
antiviral ISGs, such as viperin. Together with TRIM79α,
viperin has recently been identified as an inhibitor of
TBEV in vitro [50, 61]. Viperin has also been shown to
have antiviral activity against WNV [62]. Viperin and
TRIM79α mRNAs were quantified over time by qPCR in
WT and IFNAR−/− astrocytes and WT MEFs (Fig. 5a, b).
ISGs were rapidly induced in WT astrocytes at early
time points whereas induction was delayed in IFNAR−/−
astrocytes and WT MEFs. The basal levels of viperin
and TRIM79α were higher in WT astrocytes compared
to WT MEFs and IFNAR−/− astrocytes (Fig. 5b) and
might contribute to limit initial viral infection. Viperin
protein was also strongly induced in WT astrocytes as
early as 6 hpi whereas corresponding protein levels were
only reached after 24 hpi in IFNAR−/− astrocytes
(Fig. 5c). Together, these data show that WT astrocytes
express higher basal levels of a subset of antiviral genes
and rapidly respond upon viral infection to express anti-
viral protein that can limit viral infection. MEFs and
IFNAR−/− astrocytes show lower basal expression of
some antiviral ISGs and a delayed IFN response and ISG
Fig. 3 Astrocytes induce a fast type I IFN response upon TBEV infection which restricts virus replication. Primary WT Astrocytes (a) and MEFs (b)
were pretreated with 5000 U IFNαB/D for 16 h before infection with TBEV MOI 0.1. Viral titers were determined by focus forming assay at
indicated time points (n = 6). Primary astrocytes and MEFs were infected with TBEV using MOI 0.1. Expression levels of IFN-β (c) and IFNα2 (d) were
determined by qPCR (n = 9). Supernatants were collected at the indicated time points, and antiviral activity was determined by VSV-GFP bioassay on
MEFs (e, n = 6) or TBEV-based bioassay on WT and IFNAR−/− astrocytes (f, n = 12). g WT and IFNAR−/− astrocytes were treated with either 5000 U
IFNαB/D or virus-inactivated supernatant from WT astrocytes 24 hpi (n= 6). TBEV replication was quantified using qPCR and normalized to input viral
RNA. Mean values and standard deviations from three independent experiments are shown. *p < 0.05; **p < 0.01; ***p < 0.001
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induction which is likely to render them more
susceptible to viral infection.
IFN signaling restricts TBEV spread in astrocytes
Gene set enrichment analysis was used to identify classes
of genes overrepresented in the dataset. IFNAR−/− cells
showed a negative enrichment compared to WT in
immune pathways and interferon signaling, while the
positively enriched gene sets were below our cut-off
adjusted p value < 0.05 (Fig. 6). Both IFNαB/D and
supernatant treatment lead to enrichment in “interferon
signaling” and “interferon alpha beta signaling” (Fig. 6).
Differentially expressed genes between WT and the three
samples were analyzed using IPA to uncover predicted
activation of canonical pathways and disease functions.
Pathways involved in viral recognition and antiviral
signaling as well as functions involved in viability of
leukocytes and antiviral and inflammatory responses
were found to be downregulated in IFNAR−/− compared
to WT astrocytes (Additional file 1: Tables S3 and S4),
which can explain why the IFNAR−/− cells responded
poorly after viral infection. IPA analysis revealed activation
of pathways involved in innate immune signaling and viral
recognition, antiviral and immune response after treat-
ment with IFNαB/D and supernatant (Additional file 1:
Table S3 and S4). To extend our analyses and investigate
what might be responsible for these transcriptomic
changes, with focus on the difference between the IFNαB/
D and the supernatant treatment, we performed an IPA
upstream analysis, and a Connectivity Map (CMAP) ana-
lysis. Both of these analyses evaluate the relationship(s)
that might have led to the pattern of transcript regulation
that we found after treatment. In Fig. 7a, we have plotted
all upstream regulators that are predicted by the IPA ana-
lysis to be either activated or inhibited after IFNαB/D or
supernatant treatment. Upstream regulators that are pre-
dicted to be activated after both treatments include several
interferon regulated factors (IRF3, IRF7, STAT1) as well as
IFNAR and IFNγ as the most activated. Each dot in Fig. 7a
represents a regulator e.g., (IFN alpha/beta) with a circle
of markers of upregulated transcripts found in the dataset
(Fig. 7b). Interestingly, five upstream regulators were
Fig. 4 Astrocytes treated with either supernatant or IFNαB/D mount an antiviral response. Primary astrocytes from WT and IFNAR−/− mice were
isolated, and WT cells were either mock treated, treated with IFNαB/D, or treated with inactivated supernatant from TBEV-infected astrocytes. Gene
expression was analyzed by deep sequencing. Venn diagram of differentially expressed transcripts in IFNAR−/−, IFNαB/D, and supernatant-treated
astrocytes compared to mock-treated WT astrocytes (fold-change ±2, q value <0.05). Number of totally regulated genes (a), downregulated (b), and
upregulated (c). d Overlap of differentially expressed transcripts under all three conditions (n = 112); red color indicates an upregulation whereas blue
color correlates with a downregulation. Dynamic range in the heat map is 7.16 to −5.99 log2 fold difference compared to WT untreated astrocytes.
Sd standard deviation (n = 3)
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predicted to be activated specifically after supernatant
treatment (IL5, CD38, KMT2D, HIF1A, UCP1, and JAK2;
Fig. 7a, y-axis >2). The CMAP database is an orthogonal
bioinformatics tool that correlates specific gene-
overexpression with their associated transcriptomic
changes. Our transcriptional changes after IFNαB/D or
supernatant treatments were compared to the CMAP data-
base and the connectivity scores are compared to each
other in Fig. 7c, and top scoring genes included IFNB1,
IFNγ, and CD40. IFNγ came up in both gene set enrich-
ment analyses, IPA and CMAP (Figs. 6, 7a, b), suggesting
that TBEV induces IFNγ after infection in astrocytes. How-
ever, no differences in IFNγ mRNA expression levels were
detected after infection in astrocytes (data not shown).
With this comprehensive bioinformatics analysis, we
can show that the main gene sets enriched after super-
natant treatment are IFN signaling gene sets very similar
to the IFNαB/D treatment (Fig. 6), overall indicating that
IFNs are the main response induced after infection. We
show that IFNAR−/− astrocytes not only express lower
levels of key antiviral ISGs (Fig. 5) but also express lower
levels of ISGs, PRRs, innate immune signaling, and tran-
scription factors generally (Fig. 4d and Additional file 1:
Table S2), which probably contributes to the susceptibil-
ity of these cells (Figs. 1 and 2).
Astrocytes resistance to viral infection might be due to
high basal expression of antiviral genes, fast response via
IFNAR signaling, or both. In order to distinguish
between these possibilities, monoclonal antibodies were
used to block IFNAR signaling in WT astrocytes [63]
(Fig. 8a–c). Interestingly, the numbers of TBEV-infected
cells and TBEV replication were increased to levels simi-
lar to those measured in IFNAR−/− cells. This indicated
that response to type I IFN is more important for
restricting viral growth than the basal expression level of
antiviral ISGs. Previous studies have shown that astro-
cytes are resistant to TBEV-induced cytopathic effects
[34, 35]. We can now show that the viability of WT
Fig. 5 Astrocytes express higher baseline levels and upregulate ISGs faster after TBEV infection compared to MEFs. Primary astrocytes (WT and
IFNAR−/−) and MEFs were infected with TBEV MOI 0.1, and total cell RNA was extracted at indicated times post infection. Expression levels of
viperin and TRIM79α (a, b) were measured by qPCR analysis, normalized to the cellular GAPDH mRNA. Fold induction over mock (a) and dCT
values (b) are depicted. Mean values and standard deviations from three independent experiments performed in triplicates are shown (n = 9).
Asterisk indicates the significance level between WT astrocytes and MEF. *p < 0.05, **p < 0.01, ***p < 0.001. Protein levels of viperin, TBEV, and actin
was detected in TBEV-infected WT and IFNAR−/− astrocytes over time (c)
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astrocytes after TBEV infection is dependent on the type
1 IFN response, since IFNAR−/−, as well as WT astro-
cytes treated with an IFNAR-specific antibody, rendered
them susceptible to TBEV-induced cytopathic effect
48 hpi (Fig. 8d).
Neurons are the main target of neurotropic flavivirus
infection; however, it is not clear if and how astrocytes
influence viral growth in neurons. Therefore, superna-
tants from infected astrocytes were collected at different
time points post infection and inactivated. Primary
neurons were treated with supernatants before TBEV
infection. The number of infected neurons decreased
already when pretreated with supernatants from
astrocytes infected for 3 h (Fig. 8e). These data indicate
that astrocytes can mediate a very fast antiviral effect on
neurons already 3 h post infection.
Here, we show that astrocytes are in an antiviral state
and respond quickly to flavivirus infection by upregulat-
ing type 1 IFNs which limits neurotropic flavivirus
spread. Secreted IFNs control viral replication by upreg-
ulating several innate immune pathways and induce cell
survival. Our data suggest that although neurons seem
to represent the main target for neurotropic flavivirus
infection in vivo [64], astrocytes are likely to play an
important role in responding to infection, amplifying the
type I IFN response and limiting viral spread in both
astrocytes and neurons.
Discussion
Previous work has indicated that a local type I IFN
response is indispensable for the control of viral replica-
tion in the CNS after flavivirus infection [11]. TBEV
preferentially replicates in neurons [11, 33], but why
astrocytes are less susceptible to TBEV infection remains
unclear. In the current study, we showed that astrocytes
are initially infected by TBEV but showed strong inhib-
ition of viral spread. Astrocytes showed a higher basal
level of ISG expression which enables the cells to rapidly
respond with type I IFN production. Thus, astrocytes
induce an early and strong antiviral response that limits
viral spread in neurons and thereby plays a specific role
in the innate antiviral defense in the CNS.
Local type I IFN production is critical to limit viral
spread within the CNS [65] whereas CNS deficiency in
IFNAR increases the susceptibility of lethal virus infec-
tion [13, 17, 18, 66–68]. Using the TBEV model LGTV,
we have previously demonstrated the impact of locally
produced type I IFN response within the CNS [11];
Fig. 6 Gene set enrichment analysis of transcriptomic changes. The schematic histogram shows a typical expression profile of the transcriptomic
changes after treatment (y-axis = fold changes; x-axis = one vertical line (stick) represents one transcript; red, up; blue, down). mRNA transcripts
(sticks) and gene sets (names) that are high in IFNAR−/− astrocytes, IFNαB/D and supernatant-treated WT astrocytes, compared to WT astrocytes,
are marked as red. Genes and gene sets that are downregulated or have a negative normalized enrichment score (NES), respectively, compared
to WT astrocytes are blue. pval nominal p value, adj.pval Benjamini-Hochberg adjusted p value. An adj.pval <0.05 is regarded significant
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however, it is not clear which cells produce type I IFN in
the CNS during TBEV infection. Astrocytes have been
shown to produce an array of innate inflammatory medi-
ators upon stimulation using polyinosinic:polycytidylic
acid, lipopolysaccharide, and toll-like receptor (TLR)-7
and TLR-9 agonists [69–72]. Studies have shown that as-
trocytes are the main producers of type I IFN within the
CNS during VSV and La Cross virus infections [18, 23].
Recent studies have shown that TBEV and WNV can infect
astrocytes in vitro but fail to spread from cell to cell. How-
ever, what prevents viral spread in astrocytes is not known
[34, 36]. Our recent results show that neurons are the main
target of LGTV infection; however, a small number of as-
trocytes also become infected. During infection, astrocytes
show an activated phenotype in vivo and more cells
become infected after LGTV infection in IPS-1-deficient
mice [33], indicating that type I IFN response might
contribute to the restricted growth of virus in astrocytes.
In this study, we show that, although primary astrocytes
are infected in a comparable manner to MEF initially, viral
replication and spread is dramatically inhibited, indicating
that astrocytes are abortively infected with neurotropic
flavivirus similar to La Crosse virus infections [73]. This
phenotype is dependent on IFNAR expression, since viral
replication is uncontrolled in IFNAR-deficient astrocytes.
Consistent with previous results for WNV, we now show
for all three subtypes of TBEV, JEV, and ZIKV that the
rapidly produced type I IFN in astrocytes after neurotropic
flavivirus infection limits the viral spread and prevent
virus-induced killing of the cells.
Fig. 7 Upstream activators related to treatment with either supernatant or interferon alpha (IFN). a Scatter blot of ingenuity pathway analysis (IPA)
showing upstream regulators that are predicted to be activated (>2 activation score) or inhibited (<−2 activation score) according to experimental and
literature findings. Y-axis show upstream regulators predicted from supernatant-treated astrocytes, and x-axis show upstream regulators predicted from
IFNαB/D-treated astrocytes. Five upstream regulators show an idiosyncratic activation specific for the supernatant-treated cells, aligning the y-axis and with
an activations score of >2. b An example of predicted activators by IPA. The circle of markers is upregulated transcripts (red), and the center is a regulator
(IFN alpha/beta), predicted to be active based on information (orange arrows) in the IPA knowledge-database. Each black dot in a is representing a similar
circle of regulated markers. c Genes that, when overexpressed, lead to a similar expression pattern as either supernatant treatment (y-axis) or IFNαB/D
treatment (x-axis) according to the connectivity map database (CMAP). Genes predicted by both treatments are in the top right corner (e.g., IFNG and IFNB1)
while effects exclusive to supernatant treatment are high (>90) on the y-axis and low (<90) on the x-axis
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Weak IFN signals, transmitted independently of viral
infection, could be crucial for predisposing cells to amp-
lify their IFN production in response to viral infection
and enhance their response to other cytokines [74, 75].
Intriguingly, WT astrocytes were in an antiviral state
with higher levels of ISGs compared to MEFs, and these
were rapidly induced to even higher levels after TBEV
infection. Because no difference in basal levels of IFNβ
or IFNα2 was observed between MEFs and WT astro-
cytes (data not shown), a different mechanism compared
to IFN priming may exist [76]. However, it seems that
the responsiveness to viral infection is determined by
basal levels of innate immune components. We have
reported previously that TBEV is able to delay IFNβ
induction by hiding its dsRNA within replication vesicles
in A549 cells [42, 77] and a similar observation was
made in the MEFs in this study. No delay in type I IFN
induction was observed in astrocytes, clearly indicating
that if certain antiviral factors are present in the cell at a
basal level the virus is unable to delay the IFN response.
High basal expression of ISGs have also been linked to
viral resistance to influenza A infection in bronchial
epithelial cells [78] and contribute to neuronal tropism
of WNV [19]. Furthermore, we previously showed that
viperin is a strong inhibitor of TBEV infection [50].
Therefore, the increased basal expression of some key
ISGs could contribute to lower flavivirus replication in
astrocytes. However, the basal expression was not
enough by itself to restrict TBEV replication or spread
as neutralization of IFNAR with antibodies in WT
astrocytes rendered the WT cells susceptible to TBEV
infection. Virus infection has been shown to directly in-
duce antiviral ISGs independently of IFN signaling [79];
however, in the case of TBEV infection of astrocytes, this
response does not seem to inhibit TBEV growth.
Although IFNAR−/− astrocytes did induce ISGs at the
mRNA level and viperin at the protein level, the kinetics
were delayed compared to WTastrocytes indicating the im-
portance of a rapid IFN response in order to control TBEV
infection. To further characterize what makes the bystander
cells resistant to flavivirus infection, astrocytes were treated
with either inactivated supernatant from virus-infected cells
or with IFNαB/D followed by RNAseq. The RNAseq
revealed that IFN signaling was the most upregulated path-
way in supernatant-treated cells suggesting the IFN might
be the most important signaling molecule produced by
astrocytes upon TBEV infection. This is also true for other
viruses, as increased expression of IFN signaling molecules
and ISGs was observed in human astrocytes infected with
Junin virus [52].
Comparison of the differently expressed genes among
WT, IFNAR−/− astrocytes, supernatant or IFNαB/D-treated
WT astrocytes showed an overlap of 112 transcripts, and
these transcripts might be of particular importance as most
Fig. 8 Type I IFN response in astrocytes protects against viral spread of TBEV and cell death. Primary astrocytes isolated from WT and IFNAR−/−
mice were infected with TBEV MOI of 0.1 and viral growth was determined at indicated time points. Two hours before infection, cells were
treated with anti-IFNAR antibody or control IgG (IgC). Number of infected cells were measured by immunofluorescent staining of TBEV E antigen
and DAPI (a, n = 8). Quantification of virus RNA determined by qPCR analysis (b, n = 6). Viral titers in cell culture supernatants determined by focus
forming assay (c, n = 6). Cell viability after infection was measured using a resazurine viability assay (d, n = 8). Supernatants from TBEV-infected
astrocytes were collected at the indicated time points and inactivated. Primary neurons were pretreated with the supernatants followed by TBEV
infection, and viral infection was determined 48 h post infection by immunofluorescent staining of TBEV E antigen and DAPI (e, n = 6). Mean
values and standard deviations from three independent experiments are shown. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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of them were downregulated in IFNAR−/− astrocytes, which
were highly susceptible to TBEV infection, whereas they
were upregulated in supernatant- and IFNαB/D-treated
cells, which were resistant to the infection. Several antiviral
ISGs were identified among the overlap such as viperin and
TRIM79α, which have been identified as inhibitors of
TBEV [50, 61]. ISG15, viperin, and Oas1b, which were
found to be downregulated in IFNAR−/− astrocytes and up-
regulated after treatment with IFNαB/D and supernatant,
have previously been identified as inhibitors of WNV and
could thus contribute to antiviral response against WNV in
astrocytes [19, 62, 80, 81].
Predicting upstream regulators responsible for the
different expression patterns in IFNAR−/−-, supernatant-,
and IFNαB/D-treated astrocytes identified type I IFN as
well as IFN signaling molecules to have the highest activa-
tion scores. Similar findings were found in a previous
study where IFN signaling and antiviral mediators were
among the most upregulated pathways and genes in
WNV-infected mice brains [51]. IFNγ-STAT1-IRF-1
signaling cascade was predicted as an upstream regulator
both in supernatant and IFNαB/D-treated astrocytes.
Although IFNγ transcripts were not detected in TBEV in-
fected, astrocytes IRF-1 could be directly induced by virus
infection and could be responsible for the induction of the
overlap between inducible genes among the type I and II
IFNs [79, 82–84]. Taken together, the RNAseq confirms
the potent IFN response of the astrocytes and identifies a
subset of genes as key players in determining the outcome
of TBEV infection in astrocytes.
Previous studies have revealed that although TBEV
infects astrocytes, viral infection did not affect the viability
of the cells [34, 35]. Similar findings have been observed
with other viral infections such as WNV, JEV, and Junin
virus whereas infection with Venezuelan equine encephal-
itis virus infection induced cell death in cultured
astrocytes [31, 37, 39, 85, 86]. However, the mechanism
underlying the resistance to virus-induced cell death in
astrocytes is not well understood. Here, we show that the
type I IFN response prevents TBEV-mediated cytopathic
effect. Blocking of IFNAR using antibodies as well as
IFNAR knockout induced TBEV-mediated cell death of
astrocytes whereas the WTcontrol remained unaffected.
Conclusions
Our results show that astrocytes mount a rapid type I
IFN response upon flavivirus infection that inhibits viral
spread and replication. The IFN response also protects
astrocytes from virus-induced cell death. We further
propose that astrocytes are important IFN producers in
flavivirus infection, which can sense the viral infection
and then mediate a local IFN response within the CNS,
which could protect not only astrocytes but also other
CNS resident cells.
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